Abstract
Gram negative sepsis remains a high cause of mortality and places a great burden on public health finance in both the developed and developing world. Treatment of sepsis, using antibiotics, is often ineffective since pathology associated with the disease occurs due to dysregulation of the immune system (failure to return to steady state conditions) which continues after the bacteria, which induced the immune response, have been cleared. Immune modulation is therefore a rational approach to the treatment of sepsis but to date no drug has been developed which is highly effective, cheap and completely safe to use. One potential therapeutic agent is VIP, which is a natural peptide and is highly homologous in all vertebrates. In this review we will discuss the effect of VIP on components of the immune system, relevant to gram negative sepsis, and present data from animal models. Furthermore we will hypothesise on how these studies could be improved in future and speculate on the possible different ways in which VIP could be used in clinical medicine.
Keywords: Cytokine, inflammation, Sepsis, transcription bacteria, VIP, Systemic inflammatory response syndrome (SIRS), pathogen-associated molecular patterns (PAMPs), Toll-like receptor (TLR), cardiovascular collapse, dysregulated cytokine production, Pathogen Recognition, Therapeutic targets.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:VIP as a Potential Therapeutic Agent in Gram Negative Sepsis
Volume: 12 Issue: 4
Author(s): Hiba Ibrahim, Paul Barrow and Neil Foster
Affiliation:
Keywords: Cytokine, inflammation, Sepsis, transcription bacteria, VIP, Systemic inflammatory response syndrome (SIRS), pathogen-associated molecular patterns (PAMPs), Toll-like receptor (TLR), cardiovascular collapse, dysregulated cytokine production, Pathogen Recognition, Therapeutic targets.
Abstract: Gram negative sepsis remains a high cause of mortality and places a great burden on public health finance in both the developed and developing world. Treatment of sepsis, using antibiotics, is often ineffective since pathology associated with the disease occurs due to dysregulation of the immune system (failure to return to steady state conditions) which continues after the bacteria, which induced the immune response, have been cleared. Immune modulation is therefore a rational approach to the treatment of sepsis but to date no drug has been developed which is highly effective, cheap and completely safe to use. One potential therapeutic agent is VIP, which is a natural peptide and is highly homologous in all vertebrates. In this review we will discuss the effect of VIP on components of the immune system, relevant to gram negative sepsis, and present data from animal models. Furthermore we will hypothesise on how these studies could be improved in future and speculate on the possible different ways in which VIP could be used in clinical medicine.
Export Options
About this article
Cite this article as:
Ibrahim Hiba, Barrow Paul and Foster Neil, VIP as a Potential Therapeutic Agent in Gram Negative Sepsis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832611
DOI https://dx.doi.org/10.2174/187153012803832611 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
Current Alzheimer Research Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement
Current Vascular Pharmacology Targeting Nitrosative Stress for Neurovascular Protection: New Implications in Brain Diseases
Current Drug Targets Effects of Thiazolidinediones Beyond Glycaemic Control
Current Pharmaceutical Design Conference Report: 184th American Association for the Advancement of Science Annual Meeting, Austin TX, USA Feb. 15-19, 2018
CNS & Neurological Disorders - Drug Targets What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document
Current Vascular Pharmacology The Unaddressed Issue of Optimal Antithrombotic Treatment after Coronary Artery Stenting in Patients with an Indication for Anticoagulation: Current Evidence and Suggested Practice
Vascular Disease Prevention (Discontinued) Glycemic Variability, Oxidative Stress, and Impact on Complications Related to Type 2 Diabetes Mellitus
Current Diabetes Reviews Endothelin Receptor Antagonists - An Overview
Current Medicinal Chemistry Review of Evidence that Epidemics of Type 1 Diabetes and Type 2 Diabetes/ Metabolic Syndrome are Polar Opposite Responses to Iatrogenic Inflammation
Current Diabetes Reviews Dermatological, Cardiovascular and Neurological Morphohistopathological Effects of Fluoropyrimidine-based Chemotherapy in Humans
Clinical Cancer Drugs Medico-Legal Evaluation of Fatal Perinatal Asphyxia
Current Pediatric Reviews Advanced Glycation End Products: A Link Between Periodontitis and Diabetes Mellitus?
Current Diabetes Reviews Angiotensin-(1-7), Angiotensin-Converting Enzyme 2 and Mas Receptor in Rat Polycystic Ovaries
Protein & Peptide Letters III. Angiogenesis: Complexity of Tumor Vasculature and Microenvironment
Current Pharmaceutical Design Factor XII, Kininogen and Plasma Prekallikrein in Abnormal Pregnancies
Current Drug Targets Prayer at Midlife is Associated with Reduced Risk of Cognitive Decline in Arabic Women
Current Alzheimer Research Utility of Intrapartum Transabdominal Ultrasound for the Correct Placement of Vacuum during Assisted Delivery
Current Women`s Health Reviews Effect of Aluminium Chloride Concentration on Diltiazem Hydrochloride Release from pH-sensitive Hydrogel Beads Composed of Hydrolyzed Grafted k-Carrageenan and Sodium Alginate
Current Chemical Biology Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Endothelial Progenitor Cells (EPCs) Evaluation in Aortic Aneurysm Repair
Current Vascular Pharmacology